RenovoRx’s TIGeR-PaC Phase III trial surpasses 100 randomized patients

RenovoRx (RNXT) announced that it has achieved a key milestone in its ongoing Phase III TIGeR-PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion in the first half of 2026, with final data expected in 2027. The trial is evaluating intra-arterial gemcitabine delivered via the company’s RenovoCath device in locally advanced pancreatic cancer. “Reaching over 100 randomized patients marks an important milestone in our Phase III trial as we maintain strong momentum toward enrollment completion. We remain committed to completing the TIGeR-PaC trial and delivering final data in 2027,” said Leesa Gentry, chief clinical officer of RenovoRx. “In parallel, select TIGeR-PaC cancer centers have begun using the TAMP therapy platform, enabled by the RenovoCath device, for targeted drug-delivery in the treatment of patients diagnosed with solid tumors.”